The anti-oedematous efficacy of oxindanac equals that of paracetamol in acute postoperative inflammation; are weak cyclooxygenase inhibitors more effective than strong inhibitors?
In a double-blind crossover study, the clinical anti-oedematous efficacy was compared of a weak cyclooxygenase inhibitor oxindanac 200 mg thrice daily in a controlled clinical trial procedure with paracetamol 1 g thrice daily as a positive control involving objective measurement of acute soft tissue oedema. Paracetamol is a weak cyclooxygenase inhibitor which reduces acute postoperative tissue oedema by 30% compared to a placebo. There was no significant (p = 0.81) difference between oxindanac and paracetamol with respect to anti-oedematous activity. The present finding is discussed in view of previous results obtained in controlled trials with several other anti-inflammatory drugs, using similar objective methodology as the present one. It is proposed that non-steroidal anti-inflammatory drugs acting solely by strong inhibition of cyclooxygenase need not be optimal anti-oedematous drugs. Reasons for this proposal are discussed.
Skoglund
L A
LA
Department of Pharmacology, University of Oslo, Norway.
Eidsaunet
W
W
Pettersen
N
N
D000082:Acetaminophen / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D016861:Cyclooxygenase Inhibitors; D004311:Double-Blind Method; D004487:Edema / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007192:Indenes / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007192:Indenes; D000082:Acetaminophen; D010741:Phospholipases A; C039724:oxindanac